Argent BiopharmaRGTLF PS Ratio is 8.33 as of Jun. 28, 2026, which is 46% below its 10-year median of 15.43. The stock has 8 warning signs investors should review. Among 953 Drug Manufacturers companies, Argent Biopharma ranks worse than 78.8% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Argent Biopharma's share price is $0.025.
Argent Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00. Hence, Argent Biopharma's PS Ratio for today is 8.33.
The historical rank and industry rank for Argent Biopharma's PS Ratio or its related term are showing as below:
RGTLF'
s PS Ratio Range Over the Past 10 Years
Min: 0.26 Med: 15.43 Max: 927.42
Current: 6.17
During the past 13 years, Argent Biopharma's highest PS Ratio was 927.42. The lowest was 0.26. And the median was 15.43.
RGTLF's PS Ratio is ranked worse than 78.8% of 953
companies
in the Drug Manufacturers industry
Industry Median: 2.2
vs RGTLF: 6.17
Argent Biopharma Ltd revenue per share has been in decline for the last 5 years.
During the past 3 years, the average Revenue per Share Growth Rate was -82.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -66.30% per year.
During the past 13 years, Argent Biopharma's highest 3-Year average Revenue per Share Growth Rate was 129.80% per year. The lowest was -82.40% per year. And the median was 20.90% per year.
Back to Basics: PS Ratio
Argent Biopharma (OTCPK:RGTLF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Argent Biopharma PS Ratio Related Terms
Argent Biopharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Argent Biopharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Argent Biopharma PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Argent Biopharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Argent Biopharma's Share Price of today is $0.025.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Argent Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Argent Biopharma (RGTLF) has a PS Ratio of 8.33 as of Jun. 28, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Argent Biopharma and its competitors. This is 46% below median its historical median of 15.43. Over the past decade, Argent Biopharma's PS Ratio has ranged from 0.26 to 927.42. According to the industry distribution chart, Argent Biopharma ranks #751 out of 953 companies in the Drug Manufacturers industry, placing it in the top 78.8%.
Is Argent Biopharma's PS Ratio too high?
Argent Biopharma's current PS Ratio of 8.33 is 46% below median its 10-year median of 15.43. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 927.42. The Drug Manufacturers industry median PS Ratio is 2.20. Argent Biopharma's value of 8.33 is 278.6% above this industry median. Based on the distribution chart, Argent Biopharma ranks #751 out of 953 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Argent Biopharma's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Argent Biopharma ranks #751 out of 953 companies for PS Ratio. This places Argent Biopharma in the lower half of its industry. The industry median PS Ratio is 2.20. Argent Biopharma's value of 8.33 is 278.6% above this benchmark. Historically, Argent Biopharma's own PS Ratio has ranged from 0.26 to 927.42 over the past decade. While the company's 10-year median is 15.43 vs. the industry median of 2.20, Argent Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.20, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Argent Biopharma's current PS Ratio of 8.33 is 278.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Argent Biopharma and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Argent Biopharma's current PS Ratio is 8.33, which is 46% below median its own 10-year median of 15.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (RGTLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 25% above its estimated fair value. The current PS Ratio is 8.33, which is 46% below median its 10-year median of 15.43 and 278.6% above the Drug Manufacturers industry median of 2.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current PS Ratio is 8.33 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGTLF has been successfully added to your 